Board of Directors
As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.
CEO of HLC (Highlight Capital). Previously enrolled at USTC (University of Science and Technology of China), NYU (New York University), and LBS (London Business School). Once served in CHD, Avenue Capital (USA), Lehman Brothers (London Branch), and Becton Dickinson Healthcare Group (USA). Steven founded HLC in 2014 and manages 6 dual-currency funds (RMB/USD) a total of more than RMB 12 billion. His investment projects include Yuwell (002223), Wuxi Apptech (603259), Nayuki (02150), Mindray (300760), Pharmaron (300759), Tigermed (03347), Bright Gene (688166) and United Imagine, etc. He was awarded as Top 10 Best Investors in Healthcare in China for 2014-2019, Forbes Best Venture Capitalist in China for 2019, Top 100 Investor of Zero2IPO Investment Community in 2020.
Managing Director of Legend Capital, emphasizing on the investment in medical healthcare, particularly in medical services and IT. Jianfei has led and participated in projects including EasyDiagnosis (002932.SZ), CareRay (688607.SH), Xihua Scientific, Shengsheng Logistics, Zhixiang Biological, Quest Life Science, Asia Medicare Group, and Safe Pharmaceutical Technology, etc. Jianfei holds an engineering bachelor's degree from Shanghai Jiaotong University and a management master's degree from Tsinghua University.
Current partner of New Alliance Capital. Solid investment experience in medical healthcare, science and technology. Led projects such as Correct Seqeunce, Advaccine, Degron Therapeutics, GeneTech, PNC Processing Excellence (603690.SH), Anker Innovations (300866.SZ), and Mango Excellent Media (300413.SZ), etc.
Managing Director and Head of China Healthcare at General Atlantic. Ph.D from Johns Hopkins University School of Medicine. He has served or current serves as non-executive director of various Healthcare and Life Science companies such as Adagene, OcuMension, CanBridge and Genesis MedTech. He had also led in a USD 200+ million PIPE investment in HutchMed and named as the management advisor. Lefei was once founding partner and a member of the investment committee at Huatai Healthcare Investment Fund, and successfully led strategic investment at Mindray Medical (stock code: 300760) and MIcroPort CardioFlow Medtech (stock code: 02160.HK).
Current CTO of Biotheus. Ph.D. from Brandeis University, USA, post-doctorate at Harvard Medical School. Joanne has more than 20 years of rich experience in quality research and quality control for antibody biopharmaceutical discovery, development and launching. She has successively served as R&D executives in Abbott, Bristol-Myers Squibb, Adimab, etc., and participated in the development and quality research of many international best-selling antibody drugs. After returning to China in 2012, she served as vice president of Innovent Biologics, where she successfully established and led a quality, analysis and transfer medical team, and made significant contributions to establishment of quality system, internationalization of product quality and creation of rich product pipelines.
Current SVP of Biotheus. Ph.D., University of Oxford, UK, post-doctorate at the Shanghai Pasteur Institute of the Chinese Academy of Sciences. Served as Associate Professor at the Shanghai Pasteur Institute of the Chinese Academy of Sciences and lead three National Natural Science Foundation projects as SME. As the core scientist of the joint research project between Chinese Academy of Sciences and international pharmaceutical companies, he has published nearly 35 papers in international academic journals. Andy was once the Director New Drug Research of Innovent Biologics, responsible for the functional biology research of new tumor immunotherapy antibody drugs. During this period, as the deputy project leader, he participated and led the whole process from drug discovery, cell line development to clinical trial application of the anti-tumor antibody drug PD-1 antibody-Sintilimab. Andy also led the discovery and development of multiple therapeutic antibodies such as OX40, CD47 and LAG-3.